Browse diseases

…s on definitions of remission in lupus arthritis, hematological lupus, cardiopulmonary lupus, and CNS lupus. For other organ systems …

…tially expressed proteins between the two groups. Of those with SLE, 113/250 (45%) had active renal disease at baseline, and these …

…on, demonstrating its rapid therapeutic effect. Moderate/severe SLE and non-White race were predictive of early improvement and may…

… markedly altered across multiple immune cell subsets in active SLE. Our findings suggest that IL16 may drive differential recruitm…

…tiary education, high-income country residence. Rash, alopecia, arthritis, thrombocytopenia, leukopenia, and serologic activity were inde…

…dy suggests that patients entering this cohort of patients with SLE at a single centre have presented with milder manifestations an…

…istered 4-8 weeks after rituximab improves clinical response in systemic lupus erythematosus (SLE) patients with high baseline serum IgA2 anti-dsDNA antibod…

…ct PO:11:285 Table 1Conclusions A small subset of patients with SLE achieve prolonged remission after a single rituximab course, wi…

…plores discrepancies between physicians’ and patients’ reported Lupus disease activity and aims to identify key influencing factors.M…

…l for fatigue management than standard care. People living with SLE in the UK have a preference for live-online group FMPs than sta…

…, low disease activity SLE (n = 23), Sjogren’s Disease (n = 9), Rheumatoid Arthritis (n = 7), age- and sex-matched healthy donors (n = 17), at-risk …

…ifrolumab trials (MUSE, TULIP-1, TULIP-2) in moderate-to-severe SLE. Physicians’ assessments (clinical and laboratory data, BILAG-2…